Company profile
AARDVARK THERAPEUTICS, INC.
NASDAQ:AARDBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| DENATONIUM ACETATE MONOHYDRATE | phase3 | — | 5 | completed, terminated |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (6)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05153434 | phase2 | completed | 2022-05-27 | 2024-09-24 | Aardvark Therapeutics, Inc. | A Study of Oral ARD-101 in Patients With Prader-Willi Syndrome |
| NCT06126653 | phase2 | completed | 2024-08-01 | 2025-01-13 | Aardvark Therapeutics, Inc. | A Study to Evaluate ARD-501 in Patients With Autism Spectrum Disorder |
| NCT06828861 | phase3 | terminated | 2024-12-20 | 2026-05-07 | Aardvark Therapeutics, Inc. | ARD-101 for Treatment of PWS: The Hunger Elimination or Reduction Objective Trial |
| NCT05215847 | phase2 | completed | 2022-03-01 | 2023-02-03 | Aardvark Therapeutics, Inc. | Study to Evaluate ARD-101 in Adults Receiving Bariatric Surgery |
| NCT05121441 | phase2 | completed | 2021-11-15 | 2022-11-09 | Aardvark Therapeutics, Inc. | Study to Evaluate ARD-101 in Adults With Obesity |
FDA applications (0)
No records yet.